Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Qiagen ( (QGEN) ).
Qiagen disclosed that the Dutch financial regulator AFM has notified the company of a substantial shareholding change involving Massachusetts Financial Services Company. According to the filing, MFS now holds a combined direct and indirect interest of 7.58% of Qiagen’s share capital and 9.98% of the voting rights through various affiliated investment entities.
The announcement underscores a notable increase in institutional ownership, signaling confidence from a major asset manager in Qiagen’s equity story and governance. While Qiagen emphasized it is not responsible for the accuracy of the AFM data, the move could strengthen its shareholder base and potentially influence future voting outcomes on strategic corporate decisions.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed on major European exchanges including Frankfurt, as well as on the NYSE and Swiss markets, giving the company broad access to international investors.
Average Trading Volume: 2,172,951
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.85B
For an in-depth examination of QGEN stock, go to TipRanks’ Overview page.